Novel PARP1 Inhibitor Shows Promise in Breast Cancer
(MedPage Today) -- SAN DIEGO -- Saruparib, an investigational selective PARP1 inhibitor, showed promising activity in patients with certain homologous recombination repair (HRR)-deficient breast cancers, while limiting toxicity, according to...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Gastroschisis Repair | Hematology | Toxicology